A cardiac complication with relevant short-term toxicity is uncommon, but it is one of the severe complications after allogeneic hematopoietic stem cell transplantation (HSCT). 1 Recently, there has been increased performance of HSCT; hence late complications in long-term survivors are monitored closely. However, there are only a few reports about late-onset cardiac dysfunction. A few years ago, we experienced two patients with AML and a concomitant previously unrecognized form of very late-onset reversible cardiomyopathy in our long-term follow-up program after allogeneic HSCT.
1
On admission, angiography revealed normal coronary arteries. The myocardial uptakes of 18 fluoro-2-deoxyglucose and 99m Tctetrofosmin were normal, which implied reserved myocardial viability without inflammation. Consistent with these findings, the endomyocardial biopsies showed normal histology without lymphocytic infiltration or myofibre disarray suggestive of idiopathic dilated cardiomyopathy. Serology and histological analysis revealed no evidence of viral infection, including hepatitis B virus, hepatitis C virus, coxsackie group-B virus, adenovirus, HIV, EBV, CMV, HSV and VZV. Cultures for bacteria were all negative. Because of persistent cardiac dysfunction despite the treatment that included beta-blocker with angiotensin receptor blocker or angiotensin-converting enzyme inhibitor, prednisolone 60 mg/day (~1 mg/kg) was concurrently administered. To our surprise, cardiac functions in both patients started to improve in a week and then recovered to almost normal levels in 6 weeks ( Figure 1 , Supplementary Figure S1 ). Prednisolone was tapered gradually to maintenance level (10 mg/day) without recurrence of cardiac dysfunctions.
Recently, there has been a report that HSCT long-term survivors have a higher prevalence of atherosclerotic cardiovascular disease. 3 However, we did not find any evidence of cardiovascular disorder in our cases. Except for chemotherapy-associated irreversible cardiotoxicity, the post-transplant heart dysfunction correlated with GvHD is recognized barely but can be treated with immunosuppressive drugs. 4, 5 This condition can be severe and critical, in which it commonly occurs within 1 year post transplant with bradycardia as the manifestation. 5 Our cases are apparently distinct from previous reports because of the following reasons: (1) very late onset and (2) no coronary arteriosclerosis or myocarditis.
Some cytokines, such as TNF-α, interleukin (IL)-2 and IL-6, are known to suppress cardiac function through several mechanisms. 6 In patient 2, we observed improvement of elevated serum IL-6 and TNF-α after corticosteroid treatment (IL-6 15.2-3.3 pg/mL (normal range o4.0), TNF-α 72.0-2.5 pg/mL (o 2.8), and IL-2 within normal limits), but no assessment was performed in patient 1. Although our cases showed no bioptic findings of dilated cardiomyopathy, previous studies suggested that autoimmune abnormalities could be involved in its pathophysiology. 7 Moreover, cardiodepressant IgG3 autoantibody-directed G-proteincoupled receptors, including β1-adrenergic receptors, have been reported to have the potential to suppress cardiac function. 8 Thus, we analyzed the presence of some cardiac-specific autoantibodies against β1-adrenergic receptors, muscarinic M2-acetylcholine receptors and myosin in patient 2 before and after the corticosteroid treatment with ELISA according to previously reported methods. 9 The levels of cardiodepressant autoantibodies were measured with ex vivo system using chick embryos. 10 Interestingly, the titers of cardiodepressant autoantibodies were significantly decreased to undetectable levels after corticosteroid treatment, and ELISA revealed the presence of IgG3 autoantibodies against β1-adrenergic receptors (Table 1) . In the experimental model, anti-β1-adrenergic antibodies have been shown to act as mild β1-agonists, which is consistent with our clinical features such as tachycardia. 7 This is the first report about the presence of cardiodepressant autoantibodies in a patient with cGvHD, and these findings in patient 2 suggest that humoral factors, including cytokines and cardiosuppressive autoantibodies, can be associated with the pathophysiology of reversible cardiomyopathy. Long-term follow-up after allogeneic HSCT recently has revealed various types of complications in association with cGvHD. Although the kidney is a rare target organ in cGvHD as well as the heart, development of nephrotic range proteinuria has been recognized as a novel manifestation of cGvHD, and resolution of proteinuria with anti-CD20 antibody to support the role of B-cell dysregulation has been reported. 11 It has been appreciated that disturbances of cytokines and B-cells in cGvHD can be pathogenic without prominent inflammatory cell participation. 12 Taken together with the fact that immunosuppressive treatment is highly effective and can improve the high concentrations of cytokines and autoantibodies against the myocardium, we speculate reversible cardiomyopathy as a possible manifestation of GvHD. However, further studies are required to elucidate the association between post-allo-HSCT reversible cardiomyopathy and GvHD because multiple factors cannot be excluded thoroughly as causes of heart failure.
In conclusion, our cases suggest that steroid-responsive cardiomyopathy can be complicated in patients with cGvHD. Clinicians should be alert to this eventuality, and the cardiac function of long-term survivors after HSCT should be monitored carefully because improvement is prompt with immunosuppression besides cardioprotective drugs.
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